BioCardia Aims To Defy Precedent With A Cardiac Cell Therapy
Heart disease seems impervious to cell therapy approaches. Is biomarker stratification the answer?
You may also be interested in...
Pink Sheet’s Drug Review Profile looks at the timeline behind the development and FDA review of CellTrans’ treatment for type 1 diabetes.
Argenx has aggressive market expansion plans for Vyvgart. It also has several late-stage challengers in what is becoming a dynamic market.
Pivotal data on the oral BTK inhibitor could enable Novartis to maintain its hold on the urticaria market.